Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Dexamethasone With or Without Transplant in Newly Diagnosed Multiple Myeloma
NCT01731886Phase 4Completed
- Sponsor
- Columbia University
- Start
- Sep 2012
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lenalidomide in multiple myeloma (MM) (2 arms), sponsored by Columbia University. Primary endpoint: Complete Response Rate at 3 years. Started Sep 2012; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01731886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01731886.